AP NEWS
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from ACCESSWIRE
Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.

Intellipharmaceutics Announces Third Quarter 2019 Results

October 11, 2019 GMT
TORONTO, ON / ACCESSWIRE / October 11, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of ...
TORONTO, ON / ACCESSWIRE / October 11, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of ...

TORONTO, ON / ACCESSWIRE / October 11, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2019. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Results of Operations

The Company recorded net loss for the three months ended August 31, 2019 of $1.4 million or $0.07 per common share, compared with a net loss of $4.0 million or $0.91 per common share for the three months ended August 31, 2018. In the three months ended August 31, 2019, the lower net loss is attributed to the higher recognition of Mallinckrodt upfront fees due to the change in contract term with Mallinckrodt which expired August 31, 2019 compared to the original ten-year term and to a greater extent, sales of generic Seroquel XR® shipped to Mallinckrodt, combined with increased administrative expense related to professional and legal fees and decreased R&D expenses. In the three months ended August 31, 2018, the net loss was attributed to lower recognition of Mallinckrodt upfront fees combined with increased R&D expenses.

The Company recorded revenues of $1.7 million for the three months ended August 31, 2019 versus $0.4 million for the three months ended August 31, 2018. Such revenues consisted primarily of licensing revenues from commercial sales of the 15, 30 and 40 mg strengths of our generic Focalin XR® under the Par agreement. The higher increased revenue for the three months ended August 31, 2019 is primarily due to the change in contract term with Mallinckrodt that expired on August 31, 2019 compared to the original ten-year term. Beginning in early 2018, we began to see a significant impact from aggressive pricing by competitors, resulting in a marked increase in gross-to-net deductions such as wholesaler rebates, chargebacks and pricing adjustments. While the gross-to-net deductions fluctuate on a quarter over quarter basis, profit share payments for the last quarter has been consistent over the same period in 2018.

Expenditures for R&D for the three months ended August 31, 2019 were lower by $1.7 million compared to the three months ended August 31, 2018. The decrease is primarily due to significantly lower Biostudies and patent litigation expenses partially offset by higher third-party consulting fees.

Selling, general and administrative expenses were $1.3 million for the three months ended August 31, 2019 in comparison to $0.8 million for the three months ended August 31, 2018, resulting in an increase of $0.5 million. The increase is due to higher expenses related to administrative costs and marketing cost, partially offset by a decrease in wages and benefits.

The Company had cash of $0.05 million as at August 31, 2019 compared to $1.3 million as at May 31, 2019. The decrease in cash was mainly due to expenditures for R&D and selling, general, and administrative expenses which are partially offset by receipt from Par and cash inflow provided from financing activities. The decrease in cash during the three months ended August 31, 2019 was mainly a result of our ongoing expenditures in R&D and selling, general, and administrative expenses, which included increased legal fees.

As of August 31, 2019, our cash balance was $54,359. We currently expect to satisfy our operating cash requirements from cash on hand and quarterly profit share payments supplemented by proceeds from equity issuances as necessary. The Company may need to obtain additional funding prior to that time as we further the development of our product candidates. Potential sources of capital may include payments from licensing agreements, cost savings associated with managing operating expense levels, equity and/or debt financings and/or new strategic partnership agreements which fund some or all costs of product development. We intend to utilize the capital markets to bridge any funding shortfall and to provide capital to continue to advance our most promising product candidates. Our future operations are highly dependent upon our ability to source additional capital to support advancing our product pipeline through continued R&D activities and to fund any significant expansion of our operations. Our ultimate success will depend on whether our product candidates receive the approval of the FDA or Health Canada and whether we are able to successfully market approved products. We cannot be certain that we will be able to receive FDA or Health Canada approval for any of our current or future product candidates, that we will reach the level of sales and revenues necessary to achieve and sustain profitability, or that we can secure other capital sources on terms or in amounts sufficient to meet our needs or at all.

There can be no assurance that we will enter into new license and commercial supply agreement for the marketing and distribution of products which have been licensed under the Mallinckrodt agreement, that our products will be successfully commercialized or produce significant revenues for us. Also, there can be no assurance that we will not be required to conduct further studies for our Oxycodone ER product candidate, that the FDA will approve any of our requested abuse-deterrent label claims or that the FDA will meet its deadline for review and ultimately approve the NDA for the sale of our Oxycodone ER product candidate in the U.S. market, that we will be successful in submitting any additional ANDAs or NDAs with the FDA or Abbreviated New Drug Submissions (“ANDSs”) with Health Canada, that the FDA or Health Canada will approve any of our current or future product candidates for sale in the U.S. market and Canadian market, that any of our products or product candidates will receive regulatory approval for sale in other jurisdictions, or that any of our products will ever be successfully commercialized and produce significant revenue for us. Moreover, there can be no assurance that any of our provisional patent applications will successfully mature into patents, or that any cannabidiol-based product candidates we develop will ever be successfully commercialized or produce significant revenue for us.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s Oxycodone ER based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™ XR (pregabalin extended-release capsules).

Cautionary Statement Regarding Forward-Looking Information

Certain statements in this document constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or “forward-looking information” under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our expectations , plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, and statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs and market penetration and risks or uncertainties arising from the delisting of our shares from Nasdaq and our ability to comply with OTCQB and TSX requirements. In some cases, you can identify forward-looking statements by terminology such as “appear”, “unlikely”, “target”, “may”, “will”, “should”, “expects”, “plans”, “plans to”, “anticipates”, “believes”, “estimates”, “predicts”, “confident”, “prospects”, “potential”, “continue”, “intends”, “look forward”, “could”, “would”, “projected”, “goals” ,“set to”, “seeking” or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, , the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, capital availability, the estimated proceeds (and the expected use of any proceeds) we may receive from any offering of our securities, the potential dilutive effects of any future financing, potential liability from and costs of defending pending or future litigation, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and the difficulty in predicting the timing and results of any product launches, the timing and amount of profit-share payments from our commercial partners, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property rights for our drug delivery technologies, products and product candidates, recent and future legal developments in the United States and elsewhere that could make it more difficult and costly for us to obtain regulatory approvals for our product candidates and negatively affect the prices we may charge, increased public awareness and government scrutiny of the problems associated with the potential for abuse of opioid based medications, pursuing growth through international operations could strain our resources, our limited manufacturing, sales, marketing and distribution capability and our reliance on third parties for such, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and/or commercial partners with the ability to fund patent litigation and with acceptable product development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and commercial partners, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, delays in product approvals that may be caused by changing regulatory requirements, the difficulty in predicting the timing of regulatory approval and launch of competitive products, the difficulty in predicting the impact of competitive products on sales volume, pricing, rebates and other allowances, the number of competitive product entries, and the nature and extent of any aggressive pricing and rebate activities that may follow, the inability to forecast wholesaler demand and/or wholesaler buying patterns, seasonal fluctuations in the number of prescriptions written for our generic Focalin XR® capsules which may produce substantial fluctuations in revenue, the timing and amount of insurance reimbursement regarding our products, changes in laws and regulations affecting the conditions required by the FDA for approval, testing and labeling of drugs including abuse or overdose deterrent properties, and changes affecting how opioids are regulated and prescribed by physicians, changes in laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the effect of recent changes in U.S. federal income tax laws, including but not limited to, limitations on the deductibility of business interest, limitations on the use of net operating losses and application of the base erosion minimum tax, on our U.S. corporate income tax burden, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third-party sourced products and materials, challenges related to the development, commercialization, technology transfer, scale-up, and/or process validation of manufacturing processes for our products or product candidates, the manufacturing capacity of third-party manufacturers that we may use for our products, potential product liability risks, the recoverability of the cost of any pre-launch inventory, should a planned product launch encounter a denial or delay of approval by regulatory bodies, a delay in commercialization, or other potential issues, the successful compliance with FDA, Health Canada and other governmental regulations applicable to us and our third party manufacturers’ facilities, products and/or businesses, our reliance on commercial partners, and any future commercial partners, to market and commercialize our products and, if approved, our product candidates, difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs, challenges in securing final FDA approval for our product candidates, including our oxycodone hydrochloride extended release tablets product candidate, in particular, if a patent infringement suit is filed against us with respect to any particular product candidates (such as in the case of Oxycodone ER), which could delay the FDA’s final approval of such product candidates, healthcare reform measures that could hinder or prevent the commercial success of our products and product candidates, the risk that the FDA may not approve requested product labeling for our product candidate(s) having abuse-deterrent properties and targeting common forms of abuse (oral, intra-nasal and intravenous), risks associated with cyber-security and the potential for vulnerability of our digital information or the digital information of a current and/or future drug development or commercialization partner of ours, and risks arising from the ability and willingness of our third-party commercialization partners to provide documentation that may be required to support information on revenues earned by us from those commercialization partners. Additional risks and uncertainties relating to us and our business can be found in the “Risk Factors” section of our latest annual information form, our latest Form 20-F, and our latest Form F-1 and F-3 registration statements (including any documents forming a part thereof or incorporated by reference therein), as amended, as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Trademarks used herein are the property of their respective holders.

Unless the context otherwise requires, all references (i) to “we,” “us,” “our,” “Intellipharmaceutics,” and the “Company” refer to Intellipharmaceutics International Inc. and its subsidiaries and (ii) in this document to share amounts, per share data, share prices, exercise prices and conversion rates have been adjusted to reflect the effect of the 1-for-10 reverse split which became effective on each of Nasdaq and TSX at the open of market on September 14, 2018.The common shares of the Company are currently traded on the OTCQB and the TSX.

Nothing contained in this document should be construed to imply that the results discussed herein will necessarily continue into the future or that any conclusion reached herein will necessarily be indicative of our actual operating results.

The condensed unaudited interim consolidated financial statements, accompanying notes to the condensed unaudited interim consolidated financial statements, and Management Discussion and Analysis for the three and nine months ended August 31, 2019 will be accessible on Intellipharmaceutics’ website at www.intellipharmaceutics.com and will be available on SEDAR and EDGAR.

Summary financial tables are provided below.

Intellipharmaceutics International Inc. Condensed unaudited interim consolidated balance sheets As at August 31, 2019 and November 30, 2018 (Stated in U.S. dollars)

August 31,November 30,
20192018
$$

Assets

Current

Cash

54,3596,641,877

Accounts receivable, net

96,027239,063

Investment tax credits

1,133,849998,849

Prepaid expenses, sundry and other assets

258,235586,794

Inventory

219,928251,651
1,762,3988,718,234

Property and equipment, net

2,400,2762,755,993
4,162,67411,474,227

Liabilities

Current

Accounts payable

3,504,7552,643,437

Accrued liabilities

1,174,186353,147

Employee costs payable

236,449222,478

Conversion feature related to convertible debenture (Note 5)

129,685-

Convertible debenture

1,525,2201,790,358

Deferred revenue

-300,000
6,570,2955,309,420

Deferred revenue

-2,062,500
6,570,2957,371,920

Shareholders' equity (deficiency)

Capital stock

Authorized

Unlimited common shares without par value

Unlimited preference shares

Issued and outstanding

22,085,856 common shares

45,561,22244,327,952

(November 30, 2018 - 18,252,243)

Additional paid-in capital

44,119,24745,110,873

Accumulated other comprehensive income

284,421284,421

Accumulated deficit

(92,372,511)(85,620,939)
(2,407,621)4,102,307

Contingencies

4,162,67411,474,227

Intellipharmaceutics International Inc. Condensed unaudited interim consolidated statements of operations and comprehensive loss For the three and nine months ended August 31, 2019 and 2018 (Stated in U.S. dollars)

Three months endedNine months ended
August 31, 2019August 31, 2018August 31, 2019August 31, 2018
$$$$

Revenue

Licensing

217,265320,330881,5121,062,597

Up-front fees

1,472,67693,2252,366,485262,443
1,689,941413,5553,247,9971,325,040

Cost of good sold

Cost of goods sold

-45,29933,068111,173

Gross Margin

1,689,941368,2563,214,9291,213,867

Expenses

Research and development

1,625,3533,324,2215,412,6537,783,549

Selling, general and administrative

1,298,029792,3793,981,2852,773,698

Depreciation

126,872155,288378,932457,314
3,050,2544,271,8889,772,87011,014,561

Loss from operations

(1,360,313)(3,903,632)(6,557,941)(9,800,694)

Net foreign exchange (loss) gain

(23,767)9,406(10,138)17,106

Interest income

11886522

Interest expense

(55,720)(59,886)(169,822)(179,402)

Financing cost

(14,536)-(14,536)-

Net loss and comprehensive loss

(1,454,325)(3,954,104)(6,751,572)(9,962,968)

Loss per common share, basic and diluted

(0.07)(0.91)(0.32)(2.49)

Weighted average number of common

shares outstanding, basic and diluted

22,081,2754,353,67821,411,0174,006,582

Intellipharmaceutics International Inc. Condensed unaudited interim consolidated statements of cash flows For the three and nine months ended August 31, 2019 and 2018 (Stated in U.S. dollars)

Three months endedNine months ended
August 31, 2019August 31, 2018August 31, 2019August 31, 2018
$$$$

Net loss

(1,454,325)(3,954,104)(6,751,572)(9,962,968)

Items not affecting cash

Depreciation

125,989155,288378,932457,314

Financing cost

14,536-14,536

Stock-based compensation

51,40225,542213,691120,348

Deferred share units

---7,565

Accreted interest on convertible debenture

8,81316,36925,01148,510

Unrealized foreign exchange loss (gain)

884(14,882)884(11,365)

Change in non-cash operating assets & liabilities

Accounts receivable

198,798182,558143,036426,279

Investment tax credits

(45,000)(45,000)(135,000)(135,001)

Inventory

-(64,804)31,723(134,655)

Prepaid expenses, sundry and other assets

159,159(108,178)328,559(341,546)

Accounts payable, accrued liabilities and employee costs payable

1,319,3262,594,2831,696,3263,329,225

Deferred revenue

(1,469,716)(75,000)(2,362,500)(225,000)

Cash flows used in operating activities

(1,090,134)(1,287,928)(6,416,374)(6,421,294)

Financing activities

Repayment of principal on convertible debenture

--(300,000)-

Proceeds from issuance of shares on exercise of 2018 Pre-Funded Warrants

--27,953-

Proceed from issuance of shares and warrants

---5,300,000

2019 Debenture financing

140,800-140,800-

Debenture financing cost

(15,800)-(15,800)-

Offering costs

---(618,689)

Cash flows provided from financing activities

125,000-(147,047)4,681,311

Investing activity

Purchase of property and equipment

(10,684)(15,358)(24,097)(99,690)

Cash flows used in investing activities

(10,684)(15,358)(24,097)(99,690)

Effect of foreign exchange loss on

Cash held in foreign currency

----

Decrease in cash

(975,818)(1,303,286)(6,587,518)(1,839,673)

Cash, beginning of period

1,030,1771,360,6746,641,8771,897,061

Cash, end of period

54,35957,38854,35957,388

Supplemental cash flow information

Interest paid

29,39412,419120,14892,029

Taxes paid

----

CONTACT INFORMATION

Company Contact:

Intellipharmaceutics International Inc.

Greg Powell

Chief Financial Officer

416.798.3001 ext. 106

SOURCE: Intellipharmaceutics International Inc.

View source version on accesswire.com: